Celgene Announces Study of Bortezomib Added to Revlimid and Dexamethasone Backbone Therapy Presented at #ASH2015

Loading...
Loading...
Celgene Corporation
CELG
today announced that the addition of bortezomib to REVLIMID (lenalidomide) and low-dose dexamethasone (RVd), the standard of myeloma therapy, significantly improved progression-free survival (PFS) compared to lenalidomide and low-dose dexamethasone (Rd) in patients newly-diagnosed with multiple myeloma. The phase 3 study was conducted by SWOG, a publicly funded international cancer clinical trials network and presented at the 57th American Society of Hematology Annual Meeting. In the 471-patient study, patients receiving RVd achieved a median PFS of 43 months compared to a median PFS of 30 months for patients who received Rd alone (HR = 0.712, 96% CI, one-sided p=0.0018 (two-sided p=0.0037)). The data also show that overall survival (OS) was improved
See full press release
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...